# OnCo record egl-002 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/egl-002/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "egl-002" ;
  schema:name "EGL-002"@en ;
  schema:alternateName "anti-CCR8-IL2m"@en ;
  schema:description "EGL-002 is an experimental anti-CCR8 / IL-2 mutein fusion antibody from Egle Therapeutics, in preclinical development for solid tumours."@en ;
  schema:url <https://onco.cc/drugs/egl-002/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.egle-tx.com/egle-therapeutics-to-highlight-novel-preclinical-findings-for-regulatory-t-cells-targeting-programs-egl-001-and-egl-002-with-poster-presentations-at-the-2025-aacr-annual-meeting/>, <https://www.egle-tx.com/> ;
  onco:status "preclinical" ;
  onco:tag "pipeline" ;
  onco:modality "Anti-CCR8 / IL-2 mutein fusion antibody (targeted IL-2m)" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:targets <https://onco.cc/targets/cd25/> ;
  onco:companies <https://onco.cc/companies/egle-therapeutics/> .